Liquid chromatography-tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma

Biomedical Chromatography

Volumn 21, Issue 6, 2007, Pages 621-627

  Sparidans, Rolf W ^a   Prins, Jan M ^b   Schellens, Jan H M ^a,c   Beijnen, Jos H ^a,c,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

5 deoxy 5 fluorocytidine; Emtricitabine; LC MS MS; Nucleoside reverse transcriptase inhibitor

Indexed keywords

BIOMOLECULES; DISEASES; DRUG PRODUCTS; ELECTROSPRAY IONIZATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETERS; METABOLITES; PATIENT MONITORING; PATIENT TREATMENT; PLASMA (HUMAN);

5′-DEOXY-5-FLUOROCYTIDINE; ANALYTES; ANTIRETROVIRAL NUCLEOSIDES; EMTRICITABINE; HUMAN PLASMAS; LC-MS-MS; LC.MS/MS; NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; REVERSE-TRANSCRIPTASE; TANDEM MASS SPECTROMETRIC;

MASS SPECTROMETRY;

ABACAVIR; AMPRENAVIR; ATAZANAVIR; CAFFEINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FLUCONAZOLE; FOLIC ACID; GANCICLOVIR; INDINAVIR; ITRACONAZOLE; LAMIVUDINE; METHADONE; MORPHINE; NELFINAVIR; NEVIRAPINE; OXAZEPAM; PARACETAMOL; PYRAZINAMIDE; PYRIMETHAMINE; RANITIDINE; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; SULFAMETHOXAZOLE;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG DETERMINATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IONIZATION; LIQUID CHROMATOGRAPHY; PRECIPITATION; QUADRUPOLE MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY;

EID: 34250689554     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.797     Document Type: Article

References (15)

1. Aarnoutse RE, Verweij-van Wissen CP, Underberg WJ, Kleinnijenhuis J, Hekster YA and Burger DM. High-performance liquid chromatography of HIV protease inhibitors in human biological matrices. Journal of Chromatography B 2001; 764: 363-384.
2. Center for Drug Evaluation and Research of the US Department of Health and Human Services Food and Drug Administration. Guidance for Industry; Bioanalytical Method Validation. http://www.fda.gov/cder/ guidance/4252fnl.htm, 2001 -(accessed 19 June 2006).
3. Frampton JE and Croom KF. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. Drugs 2006; 66: 1501-1512.
4. Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH, Delehanty J, Rigney A, Mondou E, Snow A and Rousseau F. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrobial Agents and Chemotherapy 2002; 46: 1734-1740.
5. Modrzejewski KA and Herman RA. Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor. Annals of Pharmacotherapy 2004; 38: 1006-1014.
6. Molina JM, Peytavin G, Perusat S, Lascoux-Combes C, Sereni D, Rozenbaum W and Chene G. Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). HIV Medicine 2004; 5: 99-104.
7. Nelson M and Schiavone M. Emtricitabine (FTC) for the treatment of HIV infection. International Journal of Clinical Practice 2004; 58: 504-510.
8. Notari S, Bocedi A, Ippolito G, Narciso P, Pucillo LP, Tossini G, Donnorso RP, Gasparrini F and Ascenzi P. Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. Journal of Chromatography B 2006a; 831: 258-266.
9. Notari S, Mancone C, Tripodi M, Narciso P, Fasano M and Ascenzi P. Determination of anti-HIV drug concentration in human plasma by MALDI-TOF/TOF. Journal of Chromatography B 2006b; 833: 109-116.
10. Rezk NL, Crutchley RD and Kashuba AD. Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction. Journal of Chromatography B 2005; 822: 201-208.
11. Rosing H, Man WY, Doyle E, Bult A and Beijnen JH. Bioanalytical liquid chromatographic method validation. A review of current practices and procedures. Journal of Liquid Chromatography and Related Technologies 2000; 23: 329-354.
12. Saag MS. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clinical Infectious Diseases 2006; 42: 126-131.
13. Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT and Yacobi A. Bioanalytical method validation - a revisit with a decade of progress. Pharmaceutical Research 2000; 17: 1551-1557.
14. Wang LH, Begley J, St Claire RL, 3rd, Harris J, Wakeford C and Rousseau FS. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Research and Human Retroviruses 2004a; 20: 1173-1182.
15. Wang LH, Wiznia AA, Rathore MH, Chittick GE, Bakshi SS, Emmanuel PJ and Flynn PM. Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Antimicrobial Agents and Chemotherapy 2004b; 48: 183-191.